NCT04848285 (STAND-OP) is a NA clinical trial of Early Mobilization in Acute Stroke, sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau.

Who is sponsoring NCT04848285?

NCT04848285 is sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau.

What drugs are being tested in NCT04848285?

Interventions in NCT04848285: Early Mobilization, Standard care.

What condition does NCT04848285 study?

NCT04848285 studies Acute Stroke.

Is NCT04848285 still recruiting?

NCT04848285 is currently completed. Last updated 10 December 2021.

Last reviewed 2021-12-10 · How we verify

NCT04848285: STAND-OP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cerebral Blood Flow-guided Early Rehabilitation Intervention After Stroke: a Pilot Randomized Trial (STAND-OP)

Completed NA Last updated 10 December 2021

What this trial tests

NA trial testing Early Mobilization in Acute Stroke in 106 participants. Completed in 18 October 2021.

Timeline

2 April 2019

Primary endpoint
18 October 2021

18 October 2021

Quick facts

Lead sponsor	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	106
Start date	2 April 2019
Primary completion	18 October 2021
Estimated completion	18 October 2021
Sites	1 location across Spain

Drugs / interventions tested

Early Mobilization
Standard care — full drug profile →

Conditions studied

Acute Stroke — all drugs for Acute Stroke →

Sponsor

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Who can join

18 and older, any sex, with Acute Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary goal of most acute stroke interventions is to restore cerebral blood flow (CBF) in the affected region and prevent hypoperfusion during early clinical course. Diffuse optical technology offers a new opportunity for invasive, real time and bedside assessment of brain function biomarkers, including CBF. However, whether CBF monitoring can identify patients who are most likely to benefit from therapies is unclear Recently, it was suggested that the benefit of early mobilization (EM) after stroke on motor recovery may be outweighed by a deleterious effect on cerebral perfusion if cerebral autoregulation (CA) is impaired. Hypothetically, EM could improve recovery outcomes after stroke in selected patients based on CA function. Our objective is to investigate if EM leads to superior motor and functional outcome after stroke compared to standard care (SC) in selected patients based on optical biomarkers of CA and evaluate the feasibility of the clinical use of a novel transcranial optical monitoring system adapted to deliver biomarkers of CA at the bedside. The investigators designed a randomized controlled, open-labeled trial with blinded assessment of outcome end-points in a stroke unit of a tertiary stroke center. Patients with an ischemic or hemorrhagic stroke will be recruited and randomly assigned within 24 hours after symptoms onset to receive SC alone or EM in addition to SC. All patients will undergo optical monitoring of CA on admission to the Stroke Unit during the first mobilization. Randomization will be stratified by stroke severity and type of stroke. Clinical outcome will be assessed with the Postural Assessment Scale for Stroke (PASS) and modified Rankin scale at 90 days. Safety outcome will be assessed by recording the incidence of neurological deterioration, recurrence and falls.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Early Mobilization

Trials testing the same drug.

NCT06493123 — Cardiopulmonary Rehabilitation In Heart Valve Surgery · NA · recruiting
NCT05919940 — Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO ) · NA · recruiting
NCT06344468 — The Effect of Early Mobilization on Sleep, Physiological Parameters, and Length of Stay in ICU · NA · completed
NCT04983498 — Enhanced Recovery Pathway for Endoscopy · Phase 4 · withdrawn
NCT05851833 — A Retrospective Study of Early Postoperative Mobilization in the Recovery of Patients With Oral Head and Neck Tumors Who · completed

Other recruiting trials for Acute Stroke

Currently open trials in the same condition.

NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
NCT07295366 — Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Cont · Phase 4 · recruiting
NCT07355881 — mSOAR and Early Mortality in Acute Stroke · recruiting
NCT07301372 — Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemi · Phase 4 · recruiting
NCT07167550 — The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke · Phase 3 · recruiting

Other Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau trials

Trials by the same sponsor.

NCT07343882 — Quantification of Systemic Congestion by Ultrasound As a Predictor of Weaning Failure From Mechanical Ventilation · NA · not yet recruiting
NCT07530237 — Efficacy of Periarticular Vasoconstrictor Infiltration (PVI) in Reducing Bleeding and Postoperative Pain in Lumbar Fusio · active not recruiting
NCT07369310 — Comparing Biomarker-Guided DBS Programming With Standard Clinical Monopolar Programming · NA · not yet recruiting
NCT07314190 — Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodege · enrolling by invitation
NCT07239843 — Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychia · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04848285 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Last refreshed: 10 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04848285.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing